An interventional study of Surgical implantation of VW-50 in Glaucoma, sponsored by Melbourne Eye Specialists. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Melbourne Eye Specialists · Not applicable, Interventional, and Device feasibility
An investigator-initiated 10-participant Feasibility Study to assess a novel glaucoma drainage implant, VW-50.
A single-centre, investigator-initiated device Feasibility Study where 10 participants undergo glaucoma surgery for implantation of a novel implant (VW-50) and receive 12 months of follow-up.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 10 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →This is the only study on the registry with Melbourne Eye Specialists as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Key Exclusion Criteria:
VW-50 glaucoma implant
Device: Surgical implantation of VW-50
Implantation of VW-50 (alone or in combination with cataract surgery)
Primary feasibility outcome
Assessment of the ease of implantation of VW-50 in the human eye, measured by surgeon questionnaire assessment of implantation technique (custom 11-item questionnaire with 5 responses selectable per item, ranging from 'strongly disagree' to 'strongly agree')
Time frame: At study intervention
Secondary feasibility outcome 1
Duration of surgical implantation (mean, in minutes, excluding time for cataract extraction \& IOL insertion)
Time frame: At study intervention
Secondary feasibility outcome 2
Confirmation that VW-50 entry cannula was inserted into the anterior chamber (binary outcome with gonioscopy photograph evidence)
Time frame: 12 months
Safety and tolerability outcome 1
Incidence of all adverse events
Time frame: 12 months
Safety and tolerability outcome 2
Participant ocular quality of life assessed by 7-item local symptoms component of the SHPC-18 questionnaire
Time frame: 12 months
Safety and tolerability outcome 3
Best-corrected visual acuity (change compared to baseline)
Time frame: 12 months
Safety and tolerability outcome 4
Corneal endothelial cell density measured by Specular microscopy (mean change from baseline)
Time frame: 12 months
Efficacy outcome 1
Mean Intraocular pressure (IOP) reduction at each post-operative timepoint and study conclusion, in mmHg
Time frame: 12 months
Efficacy outcome 2
Reduction in concomitant IOP-lowering medications at each post-operative timepoint and study conclusion (number of medications).
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.